COVID -19: Paediatric Trials Of Covaxin May Begin In June!!Bharat Biotech may begin paediatric trials of its COVID-19 vaccine Covaxin from June, said the company’s Business Development and International Advocacy Head Dr Raches Ella on Sunday.
He also exuded confidence that vaccines for kids may get the license in the third quarter of this year.
Holding a virtual conversation with members of FICCI Ladies Organization (FLO) Hyderabad on “All about Vaccines”, he said that the company expected approval from the World Health Organization (WHO) for Covaxin by the end of the third or fourth quarter.
Responding to a question from one of the participants, Dr Ella said that Bharat Biotech will be ramping up the manufacturing capacity of Covaxin to 700 million doses by the end of this year.
“We are happy to have the full support of the government because of which we are able to stand where we are today in this journey. The vaccine is co-developed by us and ICMR. The government placed an advanced purchase order of ₹1,500 crore. This will help us to increase our risk appetite. That is why we are expanding to Bangalore and Gujarat,” added Ella.
According to him, the order had led to an increase in the company’s risk appetite. “That is why we are expanding to Bangalore and Gujarat,” he said.
Answering a question on side-effects of the vaccine among beneficiaries, Ella used an instance of injecting the purest form of water into a body.
When asked why people may still get infected with Covid-19 after taking the first dose, he replied that the first dose gives you partial efficacy.
Meanwhile, on Covid-19 prevalence among children, NITI Aayog member (Health) Dr VK Paul said on Saturday that seropositivity rate between 10-17 years is roughly the same as between 30-40 and children can also spread the infection.
“Whenever children contracted the infection then almost always symptoms are minimal, very mild disease or they are asymptomatic and because it is mild the mortality is very very less in them,” he said.
“Protecting children from infection is equally important so that they do not become part of the transmission chain,” he further said.
Indigenously produced Covaxin, along with AstraZeneca’s Covishield and recently approved Sputnik V from Russia, is being used in India for inoculating people against Covid-19.
So far, India has administered about 195,004,184 doses of vaccine against corona virus disease, the most after China and the United States.
Speaking about distribution, he said: “Right now, we are allowed to sell vaccines to the Union government, the state governments and private hospitals in the ratio of 70:20:10. If any corporate plan to inoculate their staff, they may collaborate with private hospitals.”